476 related articles for article (PubMed ID: 18608582)
1. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
[TBL] [Abstract][Full Text] [Related]
2. Chaperone-rich cell lysates, immune activation and tumor vaccination.
Zeng Y; Graner MW; Katsanis E
Cancer Immunol Immunother; 2006 Mar; 55(3):329-38. PubMed ID: 15887013
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers.
Graner MW; Zeng Y; Feng H; Katsanis E
Cancer Immunol Immunother; 2003 Apr; 52(4):226-34. PubMed ID: 12669247
[TBL] [Abstract][Full Text] [Related]
4. Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation.
Chhabra A; Mehrotra S; Chakraborty NG; Mukherji B; Dorsky DI
Eur J Immunol; 2004 Oct; 34(10):2824-33. PubMed ID: 15368298
[TBL] [Abstract][Full Text] [Related]
5. Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70.
Koide T; Iinuma H; Fukushima R
Oncol Rep; 2009 Mar; 21(3):737-46. PubMed ID: 19212634
[TBL] [Abstract][Full Text] [Related]
6. [Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells].
Zhu HC; Wu SH; Huang BY; Zhu B; Gu HH; Luo XB; Xiong Z; Chen WS
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Nov; 33(11):1012-8. PubMed ID: 19060369
[TBL] [Abstract][Full Text] [Related]
7. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.
Nair S; Wearsch PA; Mitchell DA; Wassenberg JJ; Gilboa E; Nicchitta CV
J Immunol; 1999 Jun; 162(11):6426-32. PubMed ID: 10352256
[TBL] [Abstract][Full Text] [Related]
8. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells.
Aguilera R; Saffie C; Tittarelli A; González FE; Ramírez M; Reyes D; Pereda C; Hevia D; García T; Salazar L; Ferreira A; Hermoso M; Mendoza-Naranjo A; Ferrada C; Garrido P; López MN; Salazar-Onfray F
Clin Cancer Res; 2011 Apr; 17(8):2474-83. PubMed ID: 21292818
[TBL] [Abstract][Full Text] [Related]
9. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
10. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.
Röhn TA; Schadendorf D; Sun Y; Nguyen XD; Roeder D; Langen H; Vogt AB; Kropshofer H
Eur J Immunol; 2005 Oct; 35(10):2826-39. PubMed ID: 16163671
[TBL] [Abstract][Full Text] [Related]
11. Targeting to static endosome is required for efficient cross-presentation of endoplasmic reticulum-resident oxygen-regulated protein 150-peptide complexes.
Kutomi G; Tamura Y; Okuya K; Yamamoto T; Hirohashi Y; Kamiguchi K; Oura J; Saito K; Torigoe T; Ogawa S; Hirata K; Sato N
J Immunol; 2009 Nov; 183(9):5861-9. PubMed ID: 19812200
[TBL] [Abstract][Full Text] [Related]
12. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens.
Dao T; Gomez-Nunez M; Antczak C; Kappel B; Jaggi JS; Korontsvit T; Zakhaleva V; Scheinberg DA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8763-72. PubMed ID: 16361564
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes.
Wang XH; Qin Y; Hu MH; Xie Y
Cancer Immunol Immunother; 2005 Oct; 54(10):971-80. PubMed ID: 15965645
[TBL] [Abstract][Full Text] [Related]
15. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells.
Castelli C; Ciupitu AM; Rini F; Rivoltini L; Mazzocchi A; Kiessling R; Parmiani G
Cancer Res; 2001 Jan; 61(1):222-7. PubMed ID: 11196165
[TBL] [Abstract][Full Text] [Related]
16. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity.
Brusa D; Garetto S; Chiorino G; Scatolini M; Migliore E; Camussi G; Matera L
Vaccine; 2008 Nov; 26(50):6422-32. PubMed ID: 18848858
[TBL] [Abstract][Full Text] [Related]
17. Melanoma-associated antigen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock response.
Milani V; Frankenberger B; Heinz O; Brandl A; Ruhland S; Issels RD; Noessner E
Int Immunol; 2005 Mar; 17(3):257-68. PubMed ID: 15642953
[TBL] [Abstract][Full Text] [Related]
18. Both Langerhans cells and interstitial DC cross-present melanoma antigens and efficiently activate antigen-specific CTL.
Cao T; Ueno H; Glaser C; Fay JW; Palucka AK; Banchereau J
Eur J Immunol; 2007 Sep; 37(9):2657-67. PubMed ID: 17683111
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathological approaches to human tumor immunology.
Sato N; Hirohashi Y; Tsukahara T; Kikuchi T; Sahara H; Kamiguchi K; Ichimiya S; Tamura Y; Torigoe T
Pathol Int; 2009 Apr; 59(4):205-17. PubMed ID: 19351363
[TBL] [Abstract][Full Text] [Related]
20. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
Engelhard VH; Bullock TN; Colella TA; Mullins DW
Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
